ADMA Biologics

Yahoo Finance • 3 months ago

Is ADMA Biologics Inc. (ADMA) the Best Performing Small-Cap Stock in 2024?

We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where ADMA Biologics Inc. (NASDAQ:ADMA) ranks among the best-performing small-cap stocks in 2024. The Case for Small Caps Th... Full story

Yahoo Finance • last year

ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD

RAMSEY, N.J. and BOCA RATON, Fla. and LAUREL, Md., Nov. 16, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing... Full story

Yahoo Finance • last year

ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update

3Q2023 Total Revenues of $67.3 Million, a 64% Y-o-Y Increase First-Time Positive GAAP Net Income of $2.6 Million First-Time Positive Operating Cash Flow of $12.0 Million, Growing Total Cash Balance to $74.2 Million 3Q2023 Adjusted EBITD... Full story

Yahoo Finance • last year

ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing... Full story

Yahoo Finance • 2 years ago

ADMA Biologics to Report First Quarter 2023 Financial Results on May 10, 2023

RAMSEY, N.J. and BOCA RATON, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing s... Full story

Yahoo Finance • 2 years ago

ADMA Biologics Announces Amendment to Credit Agreement

Reduces Nominal Interest Rate by 1% Provides for Improved Prepayment Flexibility Total Debt Level Unchanged Favorable Amendment Enabled by Strengthened Financial Outlook RAMSEY, N.J. and BOCA RATON, Fla., May 02, 2023 (GLOBE NEWSWIRE... Full story

Yahoo Finance • 2 years ago

ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2022 Earnings Call Transcript

ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2022 Earnings Call Transcript March 23, 2023 Operator: Good afternoon, and welcome to the ADMA Biologics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call on Thu... Full story

Yahoo Finance • 2 years ago

Institutional investors are ADMA Biologics, Inc.'s (NASDAQ:ADMA) biggest bettors and were rewarded after last week's US$53m market cap gain

Key Insights Institutions' substantial holdings in ADMA Biologics implies that they have significant influence over the company's share price The top 17 shareholders own 51% of the company Analyst forecasts along with ownership data serve... Full story

Yahoo Finance • 2 years ago

ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

4Q2022 Total Revenues of $50 Million, a 90% Y-o-Y Increase 4Q2022 Gross Profit of $14 Million, an $11 Million Y-o-Y Increase FY 2023 Total Revenue Expected to Exceed $210 Million First-Time Positive EBITDA Expected No Later than Second... Full story

Yahoo Finance • 2 years ago

ADMA Biologics to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023

RAMSEY, N.J. and BOCA RATON, Fla., March 16, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing... Full story

Yahoo Finance • 2 years ago

ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J. and BOCA RATON, Fla. and HAMMO... Full story

Yahoo Finance • 2 years ago

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance

Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase Full Year 2022 Preliminary Unaudited Total Revenues of Approximately $153-$154 Million, an 90% Increase Over Full Ye... Full story

Yahoo Finance • 2 years ago

12 Best Performing NASDAQ Stocks in 2022

In this article, we discuss 12 best performing NASDAQ stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing NASDAQ Stocks in 2022. The S&P 500 rose 0.6% to 3,844.82 on December 23, while the Nasdaq... Full story

Yahoo Finance • 2 years ago

ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®

FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life Provides for improved inventory management and ease of prod... Full story

Yahoo Finance • 2 years ago

ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing sp... Full story

Yahoo Finance • 2 years ago

ADMA Biologics Announces Proposed Public Offering of Common Stock

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing s... Full story

Yahoo Finance • 2 years ago

ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing s... Full story

Yahoo Finance • 2 years ago

ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update

3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase Raising FY 2022 Total Revenue Guidance to $145 Million From $130 Million Previously Gross Profit Grow... Full story

Yahoo Finance • 2 years ago

ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022

Conference Call Scheduled for November 9, 2022, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutic... Full story

Yahoo Finance • 2 years ago

ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J., BOCA RATON, Fla. and Myrtle B... Full story